Skip to main content

Table 3 Unadjusted regression models of androgen levels and 12- and 36-month outcomes within each sex

From: Umbilical cord blood androgen levels and ASD-related phenotypes at 12 and 36 months in an enriched risk cohort study

Androgensa

Infant sex

Outcomes

  

12-month AOSI

36-month SRS

  

Beta

95% CI

P

Beta

95% CI

P

ln(T)

Female (n = 62)

0.20

(−0.12,0.51)

0.22

−0.06

(−0.30,0.19)

0.64

Male (n = 75)

0.20

(−0.13,0.52)

0.23

0.05

(−0.25,0.36)

0.73

ln(A4)

Female (n = 62)

0.06

(−0.36,0.48)

0.78

−0.18

(−0.50,0.14)

0.26

Male (n = 75)

0.06

(−0.33,0.45)

0.76

−0.21

(−0.57,0.15)

0.24

ln(DHEA)

Female (n = 62)

0.09

(−0.19,0.37)

0.51

−0.05

(−0.25,0.16)

0.67

Male (n = 75)

0.04

(−0.28,0.34)

0.82

−0.01

(−0.31,0.29)

0.94

  1. ln natural log transformed
  2. aSeparate robust regression models of loge-transformed testosterone (T), androstenedione (A4), and dehydroepiandrostenedione (DHEA) with total loge (AOSI + 1) and loge (SRS raw) scores. Outcome measures are 12-month Autism Observation Scales for Infants (AOSI) total score and 36-month Social Responsiveness Scale (SRS) total raw score